Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Cipla
Farmers Insurance
Covington
Fish and Richardson
Daiichi Sankyo

Generated: May 21, 2019

DrugPatentWatch Database Preview

AVONEX Drug Profile

« Back to Dashboard

Summary for Tradename: AVONEX
Patents:76
Applicants:1
BLAs:1
Suppliers: see list1
Drug Prices: Drug price information for AVONEX

US Patents for AVONEX

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source
Biogen AVONEX interferon beta-1a VIAL 103628 001 1996-05-17 ➤ Try a Free Trial Schutzer; Steven E. (New York, NY) ➤ Try a Free Trial RX search
Biogen AVONEX interferon beta-1a VIAL 103628 001 1996-05-17 ➤ Try a Free Trial MERCK SERONO SA (Coinsins, Vaud, CH) ➤ Try a Free Trial RX search
Biogen AVONEX interferon beta-1a VIAL 103628 001 1996-05-17 ➤ Try a Free Trial NORTHWESTERN UNIVERSITY (Evanston, IL) ➤ Try a Free Trial RX search
Biogen AVONEX interferon beta-1a VIAL 103628 001 1996-05-17 ➤ Try a Free Trial BIOGEN MA INC. (Cambridge, MA) ➤ Try a Free Trial RX search
Biogen AVONEX interferon beta-1a VIAL 103628 001 1996-05-17 ➤ Try a Free Trial SUNSHINE LAKE PHARMA CO., LTD. (Dongguan, Guangdong, CN) ➤ Try a Free Trial RX search
Biogen AVONEX interferon beta-1a VIAL 103628 001 1996-05-17 ➤ Try a Free Trial Rani Therapeutics, LLC (San Jose, CA) ➤ Try a Free Trial RX search
Biogen AVONEX interferon beta-1a VIAL 103628 001 1996-05-17 ➤ Try a Free Trial The Scripps Research Institute (La Jolla, CA) IRM LLC (Hamilton, BM) ➤ Try a Free Trial RX search
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source

Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for AVONEX

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
CA 2014 00041 Denmark ➤ Try a Free Trial PRODUCT NAME: SOFOSBUVIR; REG. NO/DATE: EU/1/13/894/001-002 20140116
2016/052 Ireland ➤ Try a Free Trial PRODUCT NAME: DACLIZUMAB; REGISTRATION NO/DATE: EU/1/16/1107 20160701
C300681 Netherlands ➤ Try a Free Trial PRODUCT NAME: SOFOSBUVIR, DESGEWENST IN DE; REGISTRATION NO/DATE: EU/1/13/894/001-002 20140116
92513 Luxembourg ➤ Try a Free Trial PRODUCT NAME: SOFOSBUVIR ET SES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES (SOVALDI). FIRST REGISTRATION: 20140117
C20160039 00209 Estonia ➤ Try a Free Trial PRODUCT NAME: DAKLIZUMAB;REG NO/DATE: EU/1/16/1107 05.07.2016
93315 Luxembourg ➤ Try a Free Trial PRODUCT NAME: PROCEDE DE TRAITEMENT DE LA SCLEROSE MULTIPLE - DACLIZUMAB; AUTHORISATION NUMBER AND DATE: EU/1/16/1107
CA 2016 00058 Denmark ➤ Try a Free Trial PRODUCT NAME: DACLIZUMAB; REG. NO/DATE: EU/1/16/1107 20160705
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Express Scripts
Healthtrust
Teva
Moodys
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.